ENvue Medical, Inc. (FEED)

From the record

ENvue Medical, Inc.'s filings since 2017 show 35 warning events of 3 kinds: a notice about its exchange listing (8-K item 3.01, 16 times, the latest 2026-07-10); an auditor change (8-K item 4.01, 3 times, the latest 2025-08-14); a late-report notice (Form NT 10-K or NT 10-Q, 16 times, the latest 2026-08-14) (its current reports).

From the record

ENvue Medical, Inc.'s 8 filed years say what it did: revenue went from $318 thousand in fiscal 2018 to $3 million in fiscal 2025, up 34.7% a year; it rose in 5 of 7 years; the deepest fall was 56% from fiscal 2021 to fiscal 2022; net income was positive in 0 of 8 of those years (its annual reports).

From the record

Return on equity: in the fiscal year ended 2025-12-31, ENvue Medical, Inc. lost about 54 cents for every dollar of shareholders' money, and gross profitability: its products earned about 0 cents per dollar of everything the company owns. Leverage: it owed about 19 cents per dollar of assets, and net share issuance: its share count grew 2229.2% over the year (the filed statements).

From the record

ENvue Medical, Inc.'s standing among 26 graded names in its industry family: revenue of $3 million in fiscal 2025 ranks in the bottom 25% by size; a net margin of -712.3% ranks in the bottom 17%; revenue growth of 50.3% a year over the last 3 filed years ranks in the top 9% (its annual reports).

From the record

ENvue Medical, Inc.'s leadership, from its insiders' filings and its current reports: no one files under a chief executive's title, so that part is not read; the 5 officers and directors filing in the last fifteen months have been on the record a median of 10 months (bottom 3%); 14 officer or director changes were reported on Form 8-K since 2023-11-13, against the 5 people in charge now (bottom 2%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

ENvue Medical, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $4 million against no long-term debt tagged leaves 10.3% of its assets as net cash, bottom 43% of its family; cash from operations less capital spending is -369.4% of revenue (bottom 22%); a gross margin of 6% (bottom 10%); research spending of 69% of revenue (top 24%) (its annual report).

From the record

ENvue Medical, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 50.3% a year over the last three filed years against 34.7% over all 8, speeding up (top 14% of its family); the newest year grew -0.2% (bottom 22%); research spending grew 83.9% a year (top 2%); capital spending grew 171.4% a year (top 10%) (its annual reports). ENvue Medical, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

From the record

ENvue Medical, Inc.'s newest year against its own record: revenue of $3 million in fiscal 2025 came in 45.9% below the $5 million its prior three years' pace pointed to (bottom 6% of its family); net income of $18 million against a prior three-year average of $4 million (bottom 7%); a net margin of a loss larger than its revenue against losses larger than its revenue before (bottom 11%) (its annual reports).